Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep selected for Phase 3 Pancreatic Cancer trial

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Jun 22, 2023 1:15pm

279 Views

Post# 35509529

RE:ONCY pelareorep selected for Phase 3 Pancreatic Cancer trial

This is huge!

PanCAN is the sponsor, so this allows ONC access to a Phase III trial at minimal costs to the company. Less dilution is required.
The fact that PanCAN is the sponsor and invited ONC to join means that the early Goblet results are being taken seriously by influential and knowledgeable players.
The Precision Promise trial would be higher profile than the thousands of other trials on the go - higher visibility both in the medical and investment community.
The size of the clinical site list (over 20!) means a broader profile as well.
The stated trial design is fast-track in nature - meant to elevate promising treatments to approval sooner than traditional trial design.
The program info doesn't state whether Accelerated Approval is an option, but the trial design would lend itself to that possibility. One can always hope . . .